EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

Caichen Li, Jianxing He, Wenhua Liang

JAMA · 2024

DOI: 10.1001/jama.2024.15488 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Caichen Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinBreast NeoplasmsFemaleHumansAnti-Inflammatory Agents, Non-SteroidalChemotherapy, AdjuvantClinical Trials, Phase III as TopicDisease-Free SurvivalMulticenter Studies as TopicNeoplasm InvasivenessNeoplasm Recurrence, LocalPlacebosRandomized Controlled Trials as Topic

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAspirinPlacebos

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Zitieren

APA

Li, C., He, J., & Liang, W. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. https://doi.org/10.1001/jama.2024.15488

Vancouver

Li C, He J, Liang W. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 2024. doi:10.1001/jama.2024.15488

BibTeX
@article{Li2024,
  author = {Li, Caichen and He, Jianxing and Liang, Wenhua},
  title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.15488}
}
Kostenlos starten →